We are contrasting Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and Athersys Inc. (NASDAQ:ATHX) on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aevi Genomic Medicine Inc.	N/A	0.00	31.31M	-0.53	0.00
Athersys Inc.	23.95M	9.34	26.06M	-0.21	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Aevi Genomic Medicine Inc. and Athersys Inc.

Profitability

Table 2 provides Aevi Genomic Medicine Inc. and Athersys Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Aevi Genomic Medicine Inc.	0.00%	-152.1%	-122%
Athersys Inc.	-108.81%	-58.7%	-44.6%

Volatility & Risk

Aevi Genomic Medicine Inc. has a beta of 0.63 and its 37.00% less volatile than Standard & Poor’s 500. Athersys Inc.’s 150.00% less volatile than Standard & Poor’s 500 which is a result of the -0.5 beta.

Liquidity

Aevi Genomic Medicine Inc.’s Current Ratio and Quick Ratio are 3.1 and 3.1 respectively. The Current Ratio and Quick Ratio of its competitor Athersys Inc. are 4.6 and 4.6 respectively. Athersys Inc. therefore has a better chance of paying off short and long-term obligations compared to Aevi Genomic Medicine Inc.

Insider and Institutional Ownership

Roughly 19.7% of Aevi Genomic Medicine Inc. shares are held by institutional investors while 22.7% of Athersys Inc. are owned by institutional investors. Insiders held 30.2% of Aevi Genomic Medicine Inc. shares. Competitively, insiders own roughly 2.2% of Athersys Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aevi Genomic Medicine Inc.	14.56%	2.61%	4.42%	-16.31%	-1.67%	-1.67%
Athersys Inc.	2.6%	0.51%	2.6%	-19.26%	5.91%	8.84%

For the past year Aevi Genomic Medicine Inc. has -1.67% weaker performance while Athersys Inc. has 8.84% stronger performance.

Summary

Athersys Inc. beats Aevi Genomic Medicine Inc. on 8 of the 9 factors.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.